Zacks Investment Research issued a report on Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), bumping up its stock price target to $21.00 today
- Updated: October 11, 2016
Yesterday Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) traded 1.03% higher at $19.17. The company’s 50-day moving average is $19.31 and its 200-day moving average is $16.16. The last stock close price is up 21.88% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 311,932 shares of the stock were exchanged, down from an average trading volume of 587,646
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) had its target price raised to $21.00 by Zacks Investment Research in a report released 10/11/2016. The new target price indicates a possible upside of 0.10% based on the company's last stock close price.
See Chart Below
Amphastar Pharmaceuticals Inc has a 52 week low of $10.50 and a 52 week high of $21.53 with a P/E ratio of 63.93 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $17.80 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.